Advertisement

Indian Journal of Clinical Biochemistry

, Volume 34, Issue 1, pp 108–114 | Cite as

A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome

  • Anbalagan AnithasriEmail author
  • Palghat Harihara Ananthanarayanan
  • P. Veena
Original Research Article
  • 74 Downloads

Abstract

Omentin-1 and prostate specific antigen (PSA) are known to be markers of insulin resistance and hyperandrogenism respectively in polycystic ovary syndrome (PCOS). This study aimed to assess the changes in serum omentin-1 and PSA levels in PCOS patients while on treatment. Serum omentin-1, PSA, BMI and Ferriman gallwey score (FG score) were measured in 80 women with PCOS. The subjects were treated depending on their presenting complaints. The parameters were analysed at baseline and after 3 months of treatment viz. lifestyle modification (Group I), oral contraceptive pills (OCP) (Group II), clomiphene citrate (Group III), medroxy progesterone acetate (Group IV) or metformin (Group V) and was compared using paired-t test. Group II showed significant increase in serum omentin-1 (271.7 ± 112.2 vs 378.1 ± 242 ng/ml; P = 0.025) and decrease in serum PSA (0.014 ± 0.02 vs 0.005 ± 0.008 ng/ml; P = 0.027) after 3 cycles of OCP. Group I and IV also showed a decrease in serum PSA while FG score decreased in group II and group III. There was a negative correlation observed between serum omentin-1 and BMI. To conclude, PCOS women showed increase in serum omentin-1 levels after 3 cycles of OCP while serum PSA decreased after 3 months of lifestyle modification or on treatment with OCP or medroxy progesterone acetate.

Keywords

Hirsutism Omentin-1 Polycystic ovary syndrome Prostate specific antigen 

Notes

Acknowledgements

I thank JIPMER for granting permission and intramural funds for conducting this study.

Funding

The study was funded by the institute’s intramural fund.

Compliance with Ethical Standards

Conflict of interest

Dr. Anbalagan Anithasri, Dr. Palghat Harihara Ananthanarayanan and Dr. P. Veena declare that we have no conflict of interest.

Ethical Approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9.CrossRefGoogle Scholar
  2. 2.
    Yang R-Z, Lee M-J, Hu H, Pray J, Wu H-B, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006;290:E1253–61.CrossRefGoogle Scholar
  3. 3.
    Mahde A, Shaker M, Al-Mashhadani Z. Study of omentin1 and other adipokines and hormones in PCOS patients. Oman Med J. 2009;24:108–18.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun. 2011;408:339–43.CrossRefGoogle Scholar
  5. 5.
    Ukinc K, Ersoz HO, Erem C, Hacihasanoglu AB. Diagnostic value of prostate-specific antigen (PSA) and free prostate specific antigen (fPSA) in women with ovulatory and anovulatory polycystic ovary syndrome. Endocrine. 2009;35:123–9.CrossRefGoogle Scholar
  6. 6.
    Vural B, Ozkan S, Bodur H. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome? J Obstet Gynaecol Res. 2007;33:166–73.CrossRefGoogle Scholar
  7. 7.
    Mardanian F, Heidari N. Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. J Res Med Sci. 2011;16:999–1005.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Escobar-Morreale HF, Serrano-Gotarredona J, Avila S, Villar-Palasí J, Varela C, Sancho J. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab. 1998;83:2580–4.CrossRefGoogle Scholar
  9. 9.
    Kuzbari O, Dorais J, Peterson C. Endocrine disorders. Novaks Gynecol. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 1080–6.Google Scholar
  10. 10.
    Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod Oxf Engl. 2004;19:41–7.CrossRefGoogle Scholar
  11. 11.
    Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815–30.CrossRefGoogle Scholar
  12. 12.
    Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem. 1995;41:204–10.PubMedGoogle Scholar
  13. 13.
    Nagar R, Msalati AA. Changes in serum PSA during normal menstrual cycle. Indian J Clin Biochem IJCB. 2013;28:84–9.CrossRefGoogle Scholar
  14. 14.
    Guzelmeric K, Seker N, Unal O, Turan C. High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill. Gynecol Endocrinol. 2004;19:190–5.CrossRefGoogle Scholar
  15. 15.
    Escobar-Morreale HF, Avila S, Sancho J. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. J Clin Endocrinol Metab. 2000;85:2488–92.PubMedGoogle Scholar
  16. 16.
    Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab. 1997;82:777–80.CrossRefGoogle Scholar
  17. 17.
    Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M, et al. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab. 2000;85:81–4.PubMedGoogle Scholar
  18. 18.
    Obiezu CV, Scorilas A, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, et al. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:1558–61.CrossRefGoogle Scholar
  19. 19.
    Metawie M, El Sarafy T, El-Kattan S, Azab H, El-Biely M. Serum-prostatic specific antigen level as a promising marker in infertile women with polycystic ovarian disease. Middle East Fertil Soc J. 2008;13:28–32.Google Scholar
  20. 20.
    Rutanen EM, Pekonen F, Mäkinen T. Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J Clin Endocrinol Metab. 1988;66:173–80.CrossRefGoogle Scholar
  21. 21.
    Shaker M, Mashhadani ZIA, Mehdi AA. Effect of treatment with metformin on omentin-1, ghrelin and other biochemical, clinical features in PCOS patients. Oman Med J. 2010;25:289–93.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes. 2010;59:3023–31.CrossRefGoogle Scholar
  23. 23.
    Orlik B, Madej P, Owczarek A, Skałba P, Chudek J, Olszanecka-Glinianowicz M. Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014;81:529–35.CrossRefGoogle Scholar
  24. 24.
    Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010;20:143–8.CrossRefGoogle Scholar
  25. 25.
    Choi J-H, Rhee E-J, Kim K-H, Woo H-Y, Lee W-Y, Sung K-C. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011;165:789–96.CrossRefGoogle Scholar
  26. 26.
    Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011;93:21–5.CrossRefGoogle Scholar
  27. 27.
    Burelli A, Cionini R, Rinaldi E, Benelli E, Fiore E, Canale D, et al. Serum PSA levels are not affected by the menstrual cycle or the menopause, but are increased in subjects with polycystic ovary syndrome. J Endocrinol Invest. 2006;29:308–12.CrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2017

Authors and Affiliations

  • Anbalagan Anithasri
    • 1
    • 3
    Email author
  • Palghat Harihara Ananthanarayanan
    • 1
  • P. Veena
    • 2
  1. 1.Department of BiochemistryJawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)PuducherryIndia
  2. 2.Department of Obstetrics and GynecologyJawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)PuducherryIndia
  3. 3.Government Villupuram Medical CollegeVillupuramIndia

Personalised recommendations